Logo Image

David Cameron

Articles by David Cameron

TIP136 ELEGANT: Elacestrant Versus Standard Endocrine Therapy (ET) in Women and Men With Node-Positive, Estrogen Receptor–Positive (ER+), HER2-Negative (HER2–), Early Breast Cancer (eBC) With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-Label Phase 3 Study

ByAditya Bardia, MD, MPH, FASCO,Virginia Kaklamani, MD, DSc,Joyce O’Shaughnessy, MD,Peter Schmid, MD,J. Thaddeus Beck,Michelino De Laurentiis,Giuseppe Curigliano,Hope S. Rugo, MD,Carlos H. Barcenas,William J Gradishar, MD, FASCO, FACP,Michail Ignatiadis,David Cameron,Giulia Tonini,Simona Scartoni,Jennifer Crozier,Tomer Wasserman,Sara M. Tolaney, MD, MPH

TPS 28 ELEGANT: Elacestrant VS Standard Endocrine Therapy in Women and Men With Node-Positive, Estrogen Receptor-Positive, HER2-Negative, Early Breast Cancer With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-Label Phase 3 Study

ByAditya Bardia, MD, MPH, FASCO,Virginia Kaklamani, MD, DSc,Joyce A. O’Shaughnessy,Peter Schmid, MD,J. Thaddeus Beck,Michelino De Laurentiis,Guiseppe Curigliano,Hope S. Rugo, MD,Carlos Barcenas,William J Gradishar, MD, FASCO, FACP,Michail Ignatiadis,David Cameron,Giulia Tonini,Simona Scartoni,Jennifer Crozier,Leo Viana Nicacio,Tomer Wasserman,Sara M. Tolaney, MD, MPH

Latest Updated Articles